99459-47-9

Basic information

• Product Name: 1H-Benzimidazole-2-carboxylicacid,5-methyl-(9CI)
• Synonyms: 1H-Benzimidazole-2-carboxylicacid,5-methyl-(9CI);1H-benzimidazole-2-carboxylic acid, 6-methyl-;6-methyl-1H-benzimidazole-2-carboxylic acid;6-methyl-1H-benzimidazole-2-carboxylic acid(SALTDATA: FREE);6-Methyl-1H-1,3-benzodiazole-2-carboxylic acid;5-methyl-1H-benzo[d]imidazole-2-carboxylic acid;5-methyl-1H-benzimidazole-2-carboxylic acid
• CAS NO: 99459-47-9
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.174
• Product Categories: BENZIMIDAZOLE
• Mol File: 99459-47-9.mol

Chemical Properties

• Melting Point: 140 °C (decomp)
• Boiling Point: 444.5°C at 760 mmHg
• Flash Point: 222.6°C
• Appearance: /
• Density: 1.421g/cm³
• Vapor Pressure: 1.11E-08mmHg at 25°C
• Refractive Index: 1.709
• Storage Temp.: 2-8°C
• PKA: 1.52±0.30(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-2-carboxylicacid,5-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-2-carboxylicacid,5-methyl-(9CI)(99459-47-9)
• EPA Substance Registry System: 1H-Benzimidazole-2-carboxylicacid,5-methyl-(9CI)(99459-47-9)

Safety Data

• Hazardous Substances Data: 99459-47-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole-2-carboxylic acid, 5-methyl-(9CI) is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of bioactive molecules. Its unique chemical structure allows for the creation of compounds with potential therapeutic properties, making it an essential component in drug discovery and medicinal chemistry.
Used in Organic Synthesis:
In the field of organic synthesis, 1H-Benzimidazole-2-carboxylic acid, 5-methyl-(9CI) is utilized as a versatile building block for the production of a wide range of organic compounds. Its carboxylic acid and methyl group functionalities enable various chemical reactions, facilitating the synthesis of complex organic molecules with diverse applications in research and industry.
Used in Research and Development:
1H-Benzimidazole-2-carboxylic acid, 5-methyl-(9CI) is employed as a research compound in academic and industrial laboratories. Its unique structure and reactivity make it a valuable tool for exploring new chemical reactions, understanding molecular interactions, and developing innovative applications in various scientific fields.

InChI:InChI=1/C9H8N2O2/c1-5-2-3-6-7(4-5)11-8(10-6)9(12)13/h2-4H,1H3,(H,10,11)(H,12,13)

Upstream product

• 496-72-0 4-methyl-1,2-diaminobenzene 
• 3584-62-1 5-methyl-2-trichloromethyl-1H-benzoimidazole 
• 20034-02-0 (5-methyl-1H-benzimidazole-2-yl)methanol 

Relevant articles and documents

Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds have some common features; three possess 5-halo substituents; two are derivatives of (S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1Hbenzo[ d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be considered promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

Molecular properties prediction and synthesis of new benzimidazole H4-receptor antagonists as anti-inflammatory agents

This investigation deals with the design and calculation of molecular properties, drug likeness, lipophilicity and solubility parameters of substituted benzimidazolyl carbonyl piperazines/piperidines using Mol inspiration, Mol soft, Software's and ALOPGPS 2.1 program. Toxicity parameters were calculated using Osiris Software. All compounds are non toxic; fulfill the solubility requirements and passing oral bioavailability criteria. The compounds were synthesized and characterized by IR, 1H NMR and Mass spectral analysis. Most of the compounds exhibited significant antiinflammatory activity.

NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS

Unsaturated nitrogen heterocyclic compounds of formula (I): (I), as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Structure-guided design of α-amino acid-derived Pin1 inhibitors

The peptidyl prolyl cis/trans isomerase Pin1 is a promising molecular target for anti-cancer therapeutics. Here we report the structure-guided evolution of an indole 2-carboxylic acid fragment hit into a series of α-benzimidazolyl-substituted amino acids.

BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.